WO2007082979A1 - Una composición sólida de taxano liofilizada, un procedimiento para preparar dicha composición sólida, una formulación farmacéutica y un conjunto (kit) de dicha formulación - Google Patents
Una composición sólida de taxano liofilizada, un procedimiento para preparar dicha composición sólida, una formulación farmacéutica y un conjunto (kit) de dicha formulación Download PDFInfo
- Publication number
- WO2007082979A1 WO2007082979A1 PCT/ES2007/070013 ES2007070013W WO2007082979A1 WO 2007082979 A1 WO2007082979 A1 WO 2007082979A1 ES 2007070013 W ES2007070013 W ES 2007070013W WO 2007082979 A1 WO2007082979 A1 WO 2007082979A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- taxane
- composition
- solid
- lyophilization
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- the present invention pertains to the field of pharmaceutical formulations poorly soluble in water.
- it refers to formulations of oncological medications, where said medications belong to the group of taxanes and to procedures for obtaining them. More particularly formulations suitable for parenteral infusion processes in oncological chemotherapy of docetaxel and paclitaxel.
- taxanes are products extracted from the leaves and bark of a tree known as the common yew (Taxus baccata and other species of the genus Taxus), such as paclitaxel as well as semi-synthetic products obtained from baccatin III or 10-deacetylbacatin III, also extracted from yew, such as docetaxel.
- taxanes obtained from biolechnological processes.
- the medical uses of taxanes are diverse and their antitumor effects can be mentioned, among others.
- cancers that are treated with docetaxel. may be mentioned: locally advanced or metastatic breast cancer, non-small cell lung cancer, and hormone-refractory prostate cancer, ovarian cancer and stomach cancer.
- Rhone-Poulenc Sante (Courbevoie, FR) protect the current formulation of docetaxel, (US 5438072, US5698582, US5714512 and US575O561).
- This technology solves the problems of precipitation and gelation in place through a formulation that presents two solutions, one of taxane in polysorbate 80 and alcohol (which can be present in very low concentration) and the other of water and ethanol.
- These documents describe a preparation procedure that involves mixing without shaking strongly, both
- This liquid formulation of docetaxel in polysorbate 80 presents problems of stability over time, its preservation being preferred in environments with a temperature between 2 and 25 ° C.
- the presence of polysorbate 80 causes known adverse effects, due to the incorporation into the bloodstream of said surfactant in high concentrations, necessary to keep the medicine in solution. The same goes for the commercially available paclitaxel formulation that requires high concentrations of Cremophor.
- the World Health Organization has estimated that the maximum daily dose of polysorbate 80 is 25 mg / kg body weight (FAO WHO. Tech. Rep. Ser. WId. Hlth. Org. 1974, N 0 539) , so a man weighing 75 kg can receive 1,875 grams of polysorbate 80 per day; ie for a dosage of 75 mg of Taxotere per m 2 commonly used for lung or prostate cancer, a man of 75 kg weight and 1.75 m tall, has a body surface 1, 9 m2, and receive 143 mg of docetaxel accompanied by about 3.6 g of polysorbate 80 (40 mg of docetaxel per ml of Twecn 80®), which is almost double the maximum daily dosage of polysorbate 80 recommended by WHO. 6
- lyophilized formulations of some injectable medications usually have advantages over injectable liquid formulations, particularly in those cases where lyophilisate has greater chemical and physical stability; that is to say a longer period of useful life and a greater resistance to temperatures typical of warm climates, belonging to zone 4 according to the ICH, ⁇ International Committee for Harmonization).
- the material structure must meet the condition of containing spaces so that the gas produced by the sublimation of the solvent can diffuse through the mesh of the block or block.
- the block must be rigid enough to support its own structure, with the help of an excipient, if needed.
- lyophilized taxane formulations for example WO 99/24073 from Géczy, J (Thissen Laboratoires SA) proposes lyophilize docetaxel and paclitaxel from a hydroalcoholic solution of these medications and cyclodextrins.
- This solution makes it possible to obtain a lyophilisate containing the taxane complexed to a cyclodextrin as a lyophilized powder (uses 2-hydroxypropyl-beta-cyclodextrin for docetaxel in a mass ratio of approximately 1: 100 of the active ingredient toxiclodextrin).
- This lyophilisate can be dissolved in aqueous solution of up to 1 7
- this formulation incorporates a complex between cyclodextrin and taxane into the bloodstream, which can modify the important pharmacodynamic properties of taxane, so a toxicological and clinical study is required to support the use of this new complex between taxane and cyclodextrin. In addition, it involves complex procedures in its elaboration.
- Patents claiming polymer micelles are abundant in the literature, such as US 5543158 and US 6322805.
- US Pat. No. 6322805 which refers to obtaining biodegradable polymeric micelles capable of solubilizing hydrophobic drugs comprising amphiphilic block copolymers, having a hydrophilic polyalkylene oxide component and a biodegradable hydrophobic polymer selected from the group consisting of polylactic acid. polyglycolic, polylactic-co-glycolic acid, poly (epsilon-caprolactone). derivatives and mixtures thereof. Describe how the hydrophobic drug is trapped in the micelle in the absence of covalent bond. These micelles form a solution in water acting as a solubilizing agent.
- This solution can be lyophilized, preserved and reconstituted with water or isotonic solution.
- This patent does not solve the problem of increasing the solubility of the taxane as such, but rather presents a complex synthesis process of a specific copolymer to generate taxane micelles. Despite encouraging tests in terms of stability characteristics, components that radically modify both bioavailability and 9
- U.S. Patent Document Pat. No. 6780324 describes a process in which a solution of a biologically active hydrophobic agent is formed in combination with a dispersing agent, and an organic solvent or a mixture that may include water. This mixture can be lyophilized and rehydrated to form a nanodispersion or a micellar solution. This development does not lose medication in the process, can be sterilized by filtration, and a clear solution is obtained by reconstitution, but the lyophilisate does not have an agent to ensure the stability of the taxane such as an acid.
- the proposed lyophilization does not ensure that the final solid formulation is essentially free of proposed organic solvents: t-butanol, n-butanol, dioxane, pyridine, pyrimidine and piperidine; which could cause adverse effects if administered to humans.
- the proposed procedure requires operations such as sonication, intense agitation or heating to obtain the solution to lyophilize, which can either destroy the micelle or cause degradation of the taxane.
- US patent application 2004/0247624 Al of Evan Charles Unger, et al. describes another method for developing a formulation of water-soluble drugs.
- the preparation of a solid composition is proposed by lyophilizing a filtered solution of organic solvent such as terbutanol, cyclohexane, dimethyl carbonate, dimethyl sulfoxide and acetic acid, the poorly soluble medicament and at least one stabilizing agent not covalently bound to the medicament.
- organic solvent such as terbutanol, cyclohexane, dimethyl carbonate, dimethyl sulfoxide and acetic acid
- the poorly soluble medicament and at least one stabilizing agent not covalently bound to the medicament.
- the only example presented with paclitaxel (example 3) describes a complex process of sonication and heating of a mixture of two polymers in high concentration, t-butanol and the drug until it is solubilized. A lyophilization is then proposed to obtain a powder.
- a water soluble composition of taxanes refers to paclitaxel and docetaxel conjugates bound to soluble polymers, such as polyglutamic acid, polyaspartic acid, etc.
- the present invention proposes a pharmaceutical composition free of organic solvents, polysorbate 80 and polyoxyethylated castor oil, which makes the usual pretreatment with antihistamines or steroids in oncological therapies with taxanes unnecessary, and also allows to decrease the administration times by infusion.
- Lyophilisates do not meet standards such as ICH Q3C that allows residual solvent in pharmaceutical solid products of up to 0.5% acetic acid and up to 0.3% dioxane for example.
- lyophilizers used in pharmaceutical plants are prepared to lyophilize aqueous solutions, so they are generally made of stainless steel, which allows steam sterilization as required by current regulations.
- These freeze dryers are not prepared to work with organic solvents like those mentioned in the previous paragraph.
- organic solvents are toxic, corrosive, flammable or explosive.
- acetic acid is a corrosive and solvent agent such as dioxane, terbutanol and dimethyl sulfoxide, because of its toxicity and flammability they require additional infrastructure for the treatment of gases, in order to avoid contamination of production personnel and avoid accidents .
- This infrastructure, in pharmaceutical freeze-dryers of final product is very expensive and complex implementation.
- the present invention solves this problem: it proposes the freeze-drying in bulk, in a lyophilizer for the production of pharmaceutical active ingredients, of a solution of the taxane with organic lyophilization solvent, achieving a pharmaceutical active of improved solubility, which is solubilized in free aqueous solution of organic solvent and lyophilized in vials, in a pharmaceutical freeze dryer for final product. In this way the advantages of said organic lyophilization solvents are taken advantage of and at the same time a pharmaceutical free final product is obtained. 14
- said solid composition is free of polysorbate 80 and polyoxyethylated castor oil; it is sterile; it is soluble in aqueous solutions in the absence of organic solvent; and has an apparent density of between 0.05 g / ml and 0.45 g / ml; preferably an apparent density of between 0.10 g / ml and 0.35 g / ml.
- organic lyophilization solvent is selected from the group comprised of dioxane, acetic acid, dimethylsulfoxide and mixtures thereof, preferably it is dioxane or acetic acid.
- taxane from step a) is dissolved only in said organic lyophilization solvent in the absence of excipients, polymers, surfactants, lipid or protein compounds.
- said aqueous solution of step c) comprises water, acid and 16
- preparing parenteral infusion solutions for mammals, preferably humans, comprising said solid composition of said lyophilized taxane; a solubilizing composition of said solid composition of said taxane; a syringe that allows mixing said solubilizing composition with said solid composition of said taxane and obtaining a transparent and stable solution of taxane.
- said surfactant is selected from the group comprising macrogol hydroxystearate, poloxamcro, polyvinylpyrrolidone or mixtures thereof, preferably Solutol® HS 15; said acid is selected from the group comprised of citric, lactic, tartaric, ascorbic, hydrochloric acid and mixtures thereof, preferably citric acid; said lyophilization excipient is selected from the group comprised of mannitol, Lutrol® F68, sorbitol, lactose, glucose, povidone, xylitol, Kollidon® 17PF and 12PF (Kl 7PF and K12PF); and said taxane is selected from the group comprised of derivatives of baccatin III, 10-deacetylbacatin III, its conjugates, its salts, its hydrates and solvates, preferably is docetaxel, its salts, its hydrates or solvates, or paclitaxel, its salts, Your hydrates or solvates.
- taxane is understood as the compounds extracted from the leaves and bark of a tree known as the yew vulgaris (Taxus baccata and other species of the genus Taxus), such as paclitaxel, as well as semi-synthetic products obtained from of baccatin III or 10-deacetylbacatin III, also extracted from yew, such as docetaxel.
- yew vulgaris Texus baccata and other species of the genus Taxus
- paclitaxel as well as semi-synthetic products obtained from of baccatin III or 10-deacetylbacatin III, also extracted from yew, such as docetaxel.
- Synthetic and semi-synthetic analogues, conjugates, their derivatives, salts, solvates and hydrates of docetaxel and paclitaxel are also included in the definition of taxane. Also included are those taxanes obtained from biotechnological processes. 17
- taxanes are diverse and their antitumor effects can be mentioned, among others.
- cancers that are treated with docetaxel for example, there may be mentioned: locally advanced or metastatic breast cancer, non-small cell lung cancer, hormone-refractory prostate cancer, ovarian cancer and stomach cancer.
- an organic lyophilization solvent is understood as an organic solvent that has a relatively high melting point, greater than -10 0 C to allow its solidification and subsequent lyophilization, but less than 25 0 C to allow its work as a liquid to room temperature.
- acetic acid, dioxane, and dimethylsulfoxide comprise an assembly that can be used to concretize the present invention.
- These solvents allow an easy and rapid dissolution of poorly water soluble medicines, especially taxanes. without heating and without precipitation for long periods; particularly they allow to dissolve docetaxel and paclitaxel. Mixtures of these solvents are also considered organic lyophilization solvents.
- Essentially free of organic solvent means free of added organic solvents to improve solubilization such as ethanol and free of freeze-drying organic solvent. It should be noted that the phrase essentially free of organic solvent refers to that said organic lyophilization solvents are not detectable by gas chromatography with mass detector, which is capable of recording the presence of said solvents from a concentration of 0.003%.
- Terbutanol is mentioned in the state of the art as a solvent that can be used to solubilize taxanes. It is true that in mixtures with organic lyophilization solvents this is possible, but laboratory tests have indicated that this solvent does not easily and completely solubilize taxane concentrations, especially Docetaxel and paclitaxel, required for the present invention. Acetic acid and dioxane are preferred for the present invention.
- Surfactants that are likely to be used in the present invention are included in the following list: polyethylene glycol, polyvinyl pyrrolidone, poloxamers, hydroxypropyl cellulose, hydroxyethyl cellulose, polymethacrylates, polylysine, polyvinyl alcohol, acrylic polyacid, polyoxide, hyaluronic acid, hyaluronic acid its derivatives, calcium stearate, glycerol monostearate, ketostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, macrogol ethers, polyoxyethylene castor oil derivatives, polysorbates, polyethylene oxidium polysorbamate 80 polyoxyethylene stearates, sodium dodecylsulfate, calcium carboxymethylcellulose, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl cyclulose phthalate, non-crystalline cellulose, Triton.
- a preferred embodiment of the present invention comprises as surfactants macrogol hydroxystycarate, poloxamer, polyvinylpyrrolidone, povidone, or mixtures thereof.
- Lutrol® F68 is preferred.
- Solutol® HS 15 Polyethylene glycol-15-hydroxystearate
- Kollidon® 17PF or 12PF Kl 7PF or Kl 2PF
- Solutol® HS 15 is a macrogol hydroxystearate. It is also known by the following names: Polyethylene glycol-15-hydroxystearate, polyethylene glycol 660 12-hydroxystearate, macrogol-15-hydroxystearate, CAS No: 70142-34-6. It is used in injectables to solubilize hydrophobic assets and prevent sedimentation and recrystallization. Its low toxicity and extraordinary solubilizing power allow its use in high concentrations. A very low histamine release has been found after administration to mammals compared to polysorbates ("Applications of Solutol® HS 15 -A Potent Solubilizer w ⁇ th a Low Toxicity" F. Ruchatz). Some studies suggest that this solubilizer 19
- the bulk density of the lyophilisate is defined as the ratio between the mass of the block or freeze-drying block in grams and its volume in milliliters.
- the present invention provides a solid composition of lyophilized taxane, suitable for preparing pharmaceutical formulations for mammals, in particular humans, which has chemical stability, which allows storage at room temperature in tropical and subtropical climates, which facilitates the operation of preparing the infusion perfusion, which is free of toxic surfactants and excipients, in particular free of polyoxyethylated castor oil and polysorbate 80; It allows the oncological treatment of patients with hypersensitivity to said surfactants, patients with renal conditions such as saline retention syndrome, elderly patients, patients with heart failure, etc.
- said solid lyophilized taxane composition is soluble in aqueous solutions, particularly in water, is essentially free of organic solvents and has chemical stability due to the presence of acid in its formulation.
- the process of the present invention with which said solid lyophilized taxane composition can be made, consists in dissolving a taxane in an organic lyophilization solvent and subjecting said solution to a first lyophilization.
- the block or block formed which contains a concentration of lyophilization organic solvent of up to 8% by weight, is then reconstituted with aqueous solution and subjected to a second lyophilization.
- said process for preparing said solid composition of lyophilized taxane comprises the following steps:
- the present invention proposes an innovative method of double lyophilization from a taxane solution in an organic lyophilization solvent, where said solution is obtained without the need for external, mechanical or thermal means to achieve a rapid and total dissolution.
- Said solution is subjected to a first bulk lyophilization in a pharmaceutical active ingredient production freeze dryer (API), from which a freeze-dried solid block (cake) is obtained containing only said taxane and remains of the organic lyophilization solvent, This solid is the intermediate lyophilized taxane.
- API active ingredient production freeze dryer
- This intermediate lyophilized taxane thus obtained is solubilized in aqueous surfactant solution.
- freeze-drying organic solvents generate a physically stable solution, and the chemical stability of said taxanes is not affected. It has been proven that the freeze-drying block or block obtained from a solution containing only one solvent twenty-one
- solubilization of said intermediate lyophilized taxane, in aqueous surfactant solution is possible due to the particular characteristics thereof: large surface area, apparent density less than 0.1, preferably between 0.004 and 0.05 g / ml, and absence of others components.
- Taxanes such as paclitaxel or docetaxel available as commercially available APIs are not soluble in aqueous solutions in the absence of added organic solvents.
- the process of the invention allows to reduce the residual organic freeze-drying solvents in the final product, due to the second lyophilization in which the solvent is water. Residual solvent contents are achieved in the second lyophilization of less than 0.5% based on the amount of docetaxel, preferably less than 0.1%, more preferably a solid lyophilized taxane composition essentially free of organic solvent is obtained.
- the intermediate lyophilized taxane is dissolved in aqueous polymer solutions or polymer blends such as Lutrol® F68, Solutol® HSl 5, Povidone K12PF or K17PF.
- aqueous polymer solutions or polymer blends such as Lutrol® F68, Solutol® HSl 5, Povidone K12PF or K17PF.
- the additional ethanol aggregate may facilitate dissolution although physical stability generally decreases, so it is preferred not to use it.
- Kollidon® 17PF and 12PF Kl 7PF and K12PF or other, so that a solution is produced that, being lyophilized maintains the spongy structure and thus allows the easy dissolution of the solid lyophilized taxane composition of the invention, even using only water to solubilize the solid composition of lyophilized taxane for the preparation of the premix solution that is injected into the infusion solution.
- These bulk density values are, for the intermediate lyophilized laxan, less than 0.1 g / ml, preferably between 0.004 g / ml and 0.05 g / ml, more preferably between 0.006 g / ml and 0.02 g / ml . While for the solid lyophilized taxane composition of the present invention the apparent density values are those in the range of between 0.10 g / ml and 0.45 g / ml, preferably between 0.15 g / ml and 0, 35 g / ml
- docetaxel which is mainly degraded to 7-epi-docetaxel, in a percentage that can reach 60% under the conditions described.
- acid is added to the aqueous surfactant solution and then the intermediate lyophilized taxane is dissolved therein.
- the acid aggregate provides chemical stability to the solid lyophilized taxane composition of the invention.
- the acid aggregate has been shown to significantly increase the stability of the taxane to obtain said solid composition of lyophilized taxane with a purity greater than 99% in the case of docetaxel.
- acids that can be used to implement the present invention can be named: malic, tartaric, hydrochloric, citric acid, etc., any person skilled in the art will obviously determine the use of any other acid useful for pharmaceutical products.
- citric acid is used in an amount greater than 20 mg of citric acid per gram of Solutol® HS 15.
- the process of the present invention further comprises a step where it is sterilized by sterilizing membrane filtration, this filtration being performed on the solution of organic lyophilization solvent, obtained in step a), on the aqueous solution obtained in the step c) or both.
- Said sterilizing filtration is performed with 0.2 or 0.22 micron filters. This filtration is carried out prior to lyophilization, achieving by this operation a sterile powder as a solid composition of the invention.
- the solubilizing composition is also sterilized by filtration. In this way, sterilization of solids is avoided, which involves complex, expensive and risky processes for the medicine.
- the present invention also provides a pharmaceutical formulation comprising said solid lyophilized taxane composition and a solubilizing composition, which are mixed prior to use giving a clear solution.
- the present invention in a preferred embodiment, comprises an assembly consisting of a first container, which contains the solid lyophilized taxane composition of the invention; a second container containing the solubilizing composition of the invention; Y
- said syringe is prefilled and contains said recipients independent of each other, with means for communicating said containers prior to administration; and optionally with a filter.
- said syringe is prefilled and comprises said sterile compartments.
- the preparation of the perfusion formulation is simplified since both compartments are contacted, and by gentle movements the dissolution of the solid lyophilized taxane composition in said solubilizing composition is achieved and finally it is injected into the bag or bottle perfusion containing saline or dextrose.
- this prefilled syringe allows to significantly reduce the execution times, eliminating in a large percentage the risks of contamination of both the product, the nursing staff and the patient, which do exist today with the market product.
- the pharmaceutical infusion solution that is formulated with the solid lyophilized taxane composition of the present invention contains less than 1 mg / ml of taxane in normal saline or dextrose solution and also contains surfactant, preferably Solutol®, essentially free of organic solvent. .
- said pharmaceutical infusion solution for the infusion of taxanes in mammals, especially humans, for the treatment of cancer requires shorter times for the infusion process (less than 30 minutes) and does not require pretreatments with steroids or antihistamines, as It is free of polysorbate 80, free of polyoxyethylated beaver oil, free of emulsions and liposomes. 25
- Both the decrease of the operative times of preparation of the infusion solution and the decrease of the infusion times during the administration of the formulation of the invention provide the following benefits: increased patient care in the hospital system of the day of the clinical oncology services of the current health system (public and private); reduce operating costs, based on pharmacoeconomics, by better use of health resources; and prioritize the safety of health personnel involved in such manipulation (the risk of contact of the initial dilution solution with the skin and mucous membranes of the operator is reduced to almost 0).
- drugs that are likely to be used as pharmaceutical active material instead of the described taxanes, to implement the present invention are: albuterol, adapalene, doxazosin mesylate, mometasone furoate, ursodiol, amphotericin, maleate enalapril, felodipine, nefazodone hydrochloride, valrubicin, albendazole, conjugated estrogens, medroxyprogesterone acetate, nicardipine hydrochloride, zolpidem tartrate, amlodipine besylate, ethinyl estradiol, omeprazole / benzerate hydrochloride, hydrochloride deacetoxyl benzerate hydrochloride, benzoerate hydrochloride, hydrochloride benzyl hydrochloride , atovaquone, felodipine, podofilox, paricalcitol, betamethasone diprop
- celecoxib chlorthalidone, imiquimod, simvastatin, citalopram, ciprofloxacin, irinotecan hydrochloride, sparfloxacin, efavirenz, cisapride monohydrate, lansoprazole, tamsulosin hydrochloride, mofafinil, azithromycin, clarithromycin, letrozole, terbinafine hydrochloride, rosiglitazone maleate, diclofenac sodium, hydrochloride of lomefloxacin, tirofiban hydrochloride, telmisartan, diazapam, loratadine, toremifene citrate, thalidomide, dinoprostone, hydrochloride 26
- mefloquine mefloquine, trandolapril, docetaxel, mitoxantrone hydrochloride, tretinoin.
- etodoac triamcinolone acetate, estradiol, ursodiol, nelfinavir mesylate, indinavir, beclomethasone dipropionate, oxaprozin, flutamide, famotidine, nifcdipine, prednisone, cefuroxime, lorazepam.
- Type I glass vials mouth 20 mm, body diameter of 22 mm height of 27 mm, Nuova Ompi, with a nominal capacity of 7 ml were used in the experiments.
- the 20 mm freeze-dried lyophilization caps are from butyl bromide, from Helvoet Pharma.
- the solvents used are of PA quality.
- Acetic acid brand Merck art 1.00063251 1; Dioxane brand TEDIA, art DR-0480; Merck brand ethanol, art 1.00983251 1.
- the distilled water used is water quality for injectables (WFI) in accordance with USP and EP specifications.
- Solutol® HS15 registered trademark of BASF, art N "51633963; Lulrol® F68 (poloxamcr 188) brand BASF, art N 0 51633115; Lutrol® E400, brand BASF, art N 0 51632267; Kollidon® brand BASF, art N 0 : 51598188 .
- the lyophilization experiences were performed in a VlRTIS ADVANTAGE lyophilizer commanded by a MENTOR unit.
- the HPLC determinations were performed in either an HPLC BECKMAN System GoId device with model 1 solvent module 18.
- Solvent content was analyzed by means of an AGILENT TECHNOLOGIES 6890N GC system gas chromatography system with AGILENT TECHNOLOGIES 7683 B Series injector, with a PERKIN ELMER Head Space Turbo Matrix 40 sampler, and an AGILENT TECHNOLOGIES 5973 Network Mass selective mass detector detector.
- docetaxel (commercially available API) are placed and dissolved with 275 ml of dioxane. Once dissolved, it is lyophilized following a freeze-drying cycle with a freezing stage of -6O 0 C for 240 min, and lyophilization at -3 0 C for 1500 min, at 10 0 C for 1500 minutes and final drying at 3O 0 C for 1700 min at 30 0 C.
- the intermediate lyophilized taxane obtained in an amount of 6,903 g is presented as a homogeneous solid that has a bulk density of 0.025 g / ml and has a residual dioxane content of 8.6% measured by chromatography Soda and mass detector.
- the docetaxel purity of this intermediate lyophilized taxane, measured by HPLC was determined at 99.69% measured as a percentage of area, detected by UV at 232 nanometers, in HPLC using a column of 28
- anhydrous docetaxel (commercially available API), 98.2% titre, are placed on an anhydrous basis and dissolved with 160 ml of acetic acid. Once dissolved, it is sterilized by 0.22 micron filter and lyophilized following a freeze-drying cycle with a freezing stage of -6O 0 C for 240 min, and lyophilization at -5 ° C for 1500 min, at 10 0 C for 1500 minutes and final drying at 25 ° C for 380 min and 1470 min at 3O 0 C.
- the sterilized intermediate lyophilized taxane obtained in an amount of 2.18g is presented as a homogeneous looking solid, which has a bulk density of 0.014 g / ml and has a measured residual acetic acid content of 0.8%, by gas chromatography and mass detector.
- the purity of lyophilized docetaxel, measured by HPLC was determined at 99.35% measured as a percentage of area, detected by UV at 232 nanometers, in HPLC using Waters Symmetry Cl 8 stainless steel column, 4.6 mm x 15 cm, of 5 microns, and a mobile phase of Acetonitrile: methanol: water (26:32:42, v: v: v) filtered and degassed
- anhydrous docetaxel (commercially available API), 98.3% titre, are placed on an anhydrous basis and dissolved with 64 ml of acetic acid.
- a dissolved lyophilised following a lyophilisation cycle with freezing stage of -60 0 C for 240 min, and lyophilisation at -5 ° C during 2400 min, 1 O 0 C during 1500 min and final drying at 30 0 C for 1490 min.
- the intermediate lyophilized taxane obtained in 41 samples in vials of 20 mg of docetaxel each is presented as a homogeneous solid. The purity of 29
- Lyophilized docetaxel measured by HPLC was determined at 99.24% measured as a percentage of area, detected by UV at 232 nanometers, in HPLC using Waters Symmetry Cl 8 stainless steel column, 4.6 mm x 15 cm, 5 microns, and a mobile phase of Acetonitrile: methanol: water (26:32:42, v: v: v) filtered and degassed. 8 of these vials dissolve easily in a volume of 2 ml of an aqueous solution composed of Solutol® HS15: povidone (K17PF): water (25: 5: 70).
- a solid lyophilized taxane composition is obtained in the absence of acid with a docetaxel purity of 73.76% measured as a percentage of area, detected by UV at 232 nanometers, in HPLC using Waters Symmetry Cl 8 stainless steel column, 4, 6 mm x 15 cm, 5 microns, and a mobile phase of Acetonitrile: methanol: water (26:32:42, v: v: v) filtered and degassed.
- the sterile lyophilized taxane composition of the invention is obtained as a taco or block homogeneously with an apparent density of 30
- the purity of docetaxel obtained by this lyophilization process is 99.54%, measured as a percentage of area, detected by UV at 232 nanometers, in HPLC using Waters Symmetry Cl 8 stainless steel column, 4.6 mm x 15 cm , of 5 microns, and a mobile phase of Acetonitrile: methanol: water (26:32:42, v: v: v) filtered and degassed. And an undetectable residual dioxane content, measured by gas chromatography and mass detector.
- the solid lyophilized taxane composition of the sterile invention is obtained, as a taco or block homogeneously with an apparent density of 0.32 g / ml.
- the purity of docetaxel obtained by this lyophilization process is 99.70% measured as a percentage of area, detected by UV at 232 nanometers, in HPLC using Waters Symmetry C 18 stainless steel column, 4.6 mm x 15 cm, of 5 microns, and a mobile phase of Acetonitrile: methanol: water (26:32:42, v: v: v) filtered and degassed. And an undetectable residual dioxane content, measured by gas chromatography and mass detector.
- docetaxel 20 mg each are obtained, which are pre-capped and led to lyophilization following a freeze-drying cycle with a freezing stage of -6O 0 C for 240 min, and lyophilization at -5 ° C for 1500 min, at 10 0 C for 1500 minutes and final drying at 25 0 C for 5100 min.
- the sterile lyophilized solid composition obtained is presented as a block or block homogeneously, with an apparent density of 0.21 g / ml.
- the purity of docetaxel obtained by this lyophilization process is 99.64% measured as a percentage of area, detected by UV at 232 nanometers, in HPLC using Waters Symmetry C 18 stainless steel column, 4.6 mm x 15 cm, of 5 microns, and a mobile phase of Acetonitrile: methanol: water (26:32:42, v: v: v) filtered and degassed.
- the solid composition is presented as a sterile cake of homogeneously, with a bulk density of 0.32 g / ml.
- the docetaxel purity obtained by this lyophilization process is 99.46% measured as a percentage of area, detected by UV at 232 nanometers, in HPLC using Waters Symmetry Cl 8 stainless steel column, 4.6 mm x 15 cm, of 5 microns, and a mobile phase of Acetonitrile: methanol: water (26:32:42, v: v: v) filtered and degassed.
- the solid composition of the invention is sterile and is presented as a block or block homogeneously, with an apparent density of 0.32 g / ml.
- the purity of docetaxel obtained by this lyophilization process is 99.65% measured as a percentage of area, detected by UV at 232 nanometers, in HPLC using Waters Symmetry Cl 8 stainless steel column, 4.6 mm x 15 cm, of 5 microns, and a mobile phase of Acetonitrile: mctanol: water (26:32:42, v: v: v) filtered and degassed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0706932-4A BRPI0706932A2 (pt) | 2006-01-20 | 2007-01-19 | composição sólida de taxano liofilizada, procedimento para preparar dita composição sólida, formulação farmaçêutica e conjunto (kit) de dita formulação |
NZ569968A NZ569968A (en) | 2006-01-20 | 2007-01-19 | A solid lyophilized taxane composition, a method for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation |
MX2008009357A MX2008009357A (es) | 2006-01-20 | 2007-01-19 | Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion. |
US12/161,609 US20090215882A1 (en) | 2006-01-20 | 2007-01-19 | Lyophilized solid taxane composition, a process for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation |
CA002638034A CA2638034A1 (en) | 2006-01-20 | 2007-01-19 | A lyophilized solid taxane composition, a process for preparing said solid composition, a pharmaceutical formulation and a kit of said formulation |
JP2008550786A JP2009523771A (ja) | 2006-01-20 | 2007-01-19 | 凍結乾燥した個体状タキサン類組成物、前記組成物を生成する方法、前記組成物の医薬調剤、前記組成物の調剤用キット。 |
AU2007206877A AU2007206877A1 (en) | 2006-01-20 | 2007-01-19 | A solid lyophilized taxane composition, a method for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation |
EP07712570A EP1982699A1 (en) | 2006-01-20 | 2007-01-19 | A solid lyophilized taxane composition, a method for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP06100208 | 2006-01-20 | ||
AR20060100208A AR054215A1 (es) | 2006-01-20 | 2006-01-20 | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007082979A1 true WO2007082979A1 (es) | 2007-07-26 |
Family
ID=38134453
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2007/070012 WO2007082978A1 (es) | 2006-01-20 | 2007-01-18 | Una formulación farmacéutica de taxano, una composición sólida de taxano, un procedimiento para la preparación de dicha composición sólida de taxano, una composición solubilizante de dicha composición sólida de taxano, y un conjunto de elementos (kit) par |
PCT/ES2007/070013 WO2007082979A1 (es) | 2006-01-20 | 2007-01-19 | Una composición sólida de taxano liofilizada, un procedimiento para preparar dicha composición sólida, una formulación farmacéutica y un conjunto (kit) de dicha formulación |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2007/070012 WO2007082978A1 (es) | 2006-01-20 | 2007-01-18 | Una formulación farmacéutica de taxano, una composición sólida de taxano, un procedimiento para la preparación de dicha composición sólida de taxano, una composición solubilizante de dicha composición sólida de taxano, y un conjunto de elementos (kit) par |
Country Status (15)
Country | Link |
---|---|
US (2) | US20090215883A1 (es) |
EP (2) | EP1994925A4 (es) |
JP (2) | JP2009523770A (es) |
AR (1) | AR054215A1 (es) |
AU (1) | AU2007206877A1 (es) |
BR (2) | BRPI0706931A2 (es) |
CA (2) | CA2637893A1 (es) |
GT (2) | GT200800145A (es) |
MX (2) | MX2008009358A (es) |
NZ (2) | NZ569783A (es) |
PE (2) | PE20070945A1 (es) |
RU (1) | RU2429837C2 (es) |
UY (2) | UY30100A1 (es) |
WO (2) | WO2007082978A1 (es) |
ZA (2) | ZA200805704B (es) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011516587A (ja) * | 2008-04-18 | 2011-05-26 | アンジオケム,インコーポレーテッド | パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法 |
US20130131174A1 (en) * | 2010-07-05 | 2013-05-23 | Eriochem | Injectable pharmaceutical formulation of melphalan |
US8828925B2 (en) | 2008-10-15 | 2014-09-09 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
US8969310B2 (en) | 2005-07-15 | 2015-03-03 | Angiochem Inc. | Potentiation of anticancer agents |
US9161988B2 (en) | 2009-07-02 | 2015-10-20 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
US9173891B2 (en) | 2009-04-20 | 2015-11-03 | Angiochem, Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
US9221867B2 (en) | 2003-01-06 | 2015-12-29 | Angiochem Inc. | Method for transporting a compound across the blood-brain barrier |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2526996T3 (da) * | 2002-12-20 | 2019-12-02 | Xeris Pharmaceuticals Inc | Formulering til intrakutan injektion |
ES2383901T5 (es) | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080262078A1 (en) * | 2007-04-20 | 2008-10-23 | Namdeo Alok B | Pharmaceutical Compositions |
KR20100023862A (ko) * | 2007-06-22 | 2010-03-04 | 싸이도우스 엘엘씨. | 트윈 80을 함유하지 않은 도세탁셀의 용해 제제 |
US20090088393A1 (en) * | 2007-09-28 | 2009-04-02 | Zomanex, Llc | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
AR063111A1 (es) * | 2007-10-03 | 2008-12-30 | Eriochem Sa | Una formulacion farmaceutica de taxano |
KR101478779B1 (ko) | 2007-11-22 | 2015-01-05 | 에스케이케미칼주식회사 | 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법 |
MX340670B (es) * | 2009-08-25 | 2016-07-20 | Abraxis Bioscience Llc * | Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog. |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
CA2785926A1 (en) * | 2009-12-31 | 2011-07-07 | Mannkind Corporation | Injectable formulations for parenteral administration |
TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前-乳劑調配物及其製造與使用之方法 |
MX341082B (es) | 2010-05-03 | 2016-08-08 | Teikoku Pharma Usa Inc | Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas. |
WO2012012460A1 (en) | 2010-07-19 | 2012-01-26 | Xeris Pharmaceuticals, Inc. | Stable glucagon formulations for the treatment of hypoglycemia |
CN103442695B (zh) | 2011-03-10 | 2016-05-04 | Xeris药物公司 | 肠胃外注射用肽药物的稳定制剂 |
CA2853942C (en) | 2011-10-31 | 2020-08-25 | Xeris Pharmaceuticals, Inc. | Formulations for the treatment of diabetes |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
WO2014127802A1 (en) * | 2013-02-19 | 2014-08-28 | Synthon Bv | Stable compositions of bendamustine |
AU2015300944B2 (en) | 2014-08-06 | 2019-07-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
EP2985038A1 (en) * | 2014-08-12 | 2016-02-17 | Azad Pharma AG | Lyophilized API preparation |
WO2016090240A1 (en) * | 2014-12-04 | 2016-06-09 | Astex Pharmaceuticals, Inc. | Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs |
US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
JP6921759B2 (ja) * | 2015-06-04 | 2021-08-18 | クリティテック・インコーポレイテッド | 捕集装置および使用法 |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
TWI752750B (zh) | 2015-09-30 | 2022-01-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
AU2017246316B2 (en) | 2016-04-04 | 2022-09-29 | Crititech, Inc. | Methods for solid tumor treatment |
RU2708329C2 (ru) * | 2016-05-31 | 2019-12-05 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Материал стволовых клеток, композиции и способы применения |
CN117085022A (zh) | 2017-06-02 | 2023-11-21 | Xeris药物公司 | 抗沉淀的小分子药物制剂 |
SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
CA3063436A1 (en) | 2017-06-14 | 2018-12-20 | Crititech, Inc. | Methods for treating lung disorders |
JP7317804B2 (ja) * | 2017-09-07 | 2023-07-31 | シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド | ドセタキセル結合体の医薬組成物及び調製方法 |
CA3076919A1 (en) | 2017-10-03 | 2019-04-11 | Crititech, Inc. | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer |
CN107496352A (zh) * | 2017-10-13 | 2017-12-22 | 深圳万乐药业有限公司 | 一种多烯紫杉醇药物组合物及其制备方法 |
EP3827822A4 (en) * | 2018-07-25 | 2022-05-04 | Bika Biotechnology (Guangzhou) Co., Ltd. | COMPOSITION OF DOCETAXEL FOR INJECTION AND METHOD FOR PREPARING IT |
KR20220002860A (ko) | 2018-12-21 | 2022-01-07 | 모드라 파마슈티컬스 비.브이. | 피크 혈장 수준의 제어에 의한 도세탁셀을 사용하는 암 치료 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000072827A2 (en) * | 1999-05-27 | 2000-12-07 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20030099674A1 (en) * | 2001-08-11 | 2003-05-29 | Chen Andrew X. | Lyophilized injectable formulations containing paclitaxel or other taxoid drugs |
US20030175313A1 (en) * | 2002-03-18 | 2003-09-18 | Garrec Dorothee Le | Preparation of sterile stabilized nanodispersions |
US20030185894A1 (en) * | 2002-03-29 | 2003-10-02 | Acs Dobfar S.P.A. | Process for producing nanoparticles of paclitaxel and albumin |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
KR0180334B1 (ko) | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
HUP9701945A3 (en) | 1997-11-10 | 2000-04-28 | Hexal Ag | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
US5922754A (en) | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
US6630121B1 (en) | 1999-06-09 | 2003-10-07 | The Regents Of The University Of Colorado | Supercritical fluid-assisted nebulization and bubble drying |
US20010047162A1 (en) * | 2000-02-17 | 2001-11-29 | Yasumi Yugari | Injection kit and injection device |
KR20010100194A (ko) | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
EP1280557B1 (en) * | 2000-05-12 | 2012-06-20 | Samyang Corporation | Method for the preparation of polymeric micelle via phase separation of block copolymer |
CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
PL203300B1 (pl) * | 2000-10-31 | 2009-09-30 | Akad Medyczna | Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego |
WO2002043765A2 (en) | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
US20040256749A1 (en) | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
US7037528B2 (en) | 2000-12-22 | 2006-05-02 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
KR100573289B1 (ko) | 2002-07-20 | 2006-04-24 | 대화제약 주식회사 | 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법 |
KR100508518B1 (ko) | 2002-11-13 | 2005-08-17 | 한미약품 주식회사 | 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체 |
US6759539B1 (en) * | 2003-02-27 | 2004-07-06 | Chaichem Pharmaceuticals International | Process for isolation and purification of paclitaxel from natural sources |
US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
US20050152979A1 (en) | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
KR20050099311A (ko) * | 2004-04-09 | 2005-10-13 | 에이엔에이치 케어연구소(주) | 주사제용 항암제 조성물 |
US7345093B2 (en) * | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
BRPI0600194A (pt) * | 2006-01-30 | 2007-10-23 | Quiral Quimica Do Brasil S A | composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas |
CN1850056A (zh) * | 2006-03-06 | 2006-10-25 | 杨典忠 | 多西他赛冻干粉针及其制备方法 |
AR063111A1 (es) * | 2007-10-03 | 2008-12-30 | Eriochem Sa | Una formulacion farmaceutica de taxano |
-
2006
- 2006-01-20 AR AR20060100208A patent/AR054215A1/es unknown
-
2007
- 2007-01-18 WO PCT/ES2007/070012 patent/WO2007082978A1/es active Application Filing
- 2007-01-18 CA CA002637893A patent/CA2637893A1/en not_active Abandoned
- 2007-01-18 NZ NZ569783A patent/NZ569783A/en not_active IP Right Cessation
- 2007-01-18 BR BRPI0706931-6A patent/BRPI0706931A2/pt not_active IP Right Cessation
- 2007-01-18 JP JP2008550785A patent/JP2009523770A/ja active Pending
- 2007-01-18 EP EP07712569A patent/EP1994925A4/en not_active Withdrawn
- 2007-01-18 MX MX2008009358A patent/MX2008009358A/es unknown
- 2007-01-18 US US12/161,625 patent/US20090215883A1/en not_active Abandoned
- 2007-01-18 RU RU2008133761/15A patent/RU2429837C2/ru not_active IP Right Cessation
- 2007-01-19 US US12/161,609 patent/US20090215882A1/en not_active Abandoned
- 2007-01-19 CA CA002638034A patent/CA2638034A1/en not_active Abandoned
- 2007-01-19 NZ NZ569968A patent/NZ569968A/en not_active IP Right Cessation
- 2007-01-19 WO PCT/ES2007/070013 patent/WO2007082979A1/es active Application Filing
- 2007-01-19 UY UY30100A patent/UY30100A1/es not_active Application Discontinuation
- 2007-01-19 UY UY30099A patent/UY30099A1/es not_active Application Discontinuation
- 2007-01-19 ZA ZA200805704A patent/ZA200805704B/xx unknown
- 2007-01-19 BR BRPI0706932-4A patent/BRPI0706932A2/pt not_active IP Right Cessation
- 2007-01-19 JP JP2008550786A patent/JP2009523771A/ja not_active Abandoned
- 2007-01-19 PE PE2007000062A patent/PE20070945A1/es not_active Application Discontinuation
- 2007-01-19 PE PE2007000063A patent/PE20071243A1/es not_active Application Discontinuation
- 2007-01-19 AU AU2007206877A patent/AU2007206877A1/en not_active Abandoned
- 2007-01-19 EP EP07712570A patent/EP1982699A1/en not_active Withdrawn
- 2007-01-19 MX MX2008009357A patent/MX2008009357A/es not_active Application Discontinuation
-
2008
- 2008-07-09 ZA ZA200805989A patent/ZA200805989B/xx unknown
- 2008-07-18 GT GT200800145A patent/GT200800145A/es unknown
- 2008-07-18 GT GT200800146A patent/GT200800146A/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000072827A2 (en) * | 1999-05-27 | 2000-12-07 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20030099674A1 (en) * | 2001-08-11 | 2003-05-29 | Chen Andrew X. | Lyophilized injectable formulations containing paclitaxel or other taxoid drugs |
US20030175313A1 (en) * | 2002-03-18 | 2003-09-18 | Garrec Dorothee Le | Preparation of sterile stabilized nanodispersions |
US20030185894A1 (en) * | 2002-03-29 | 2003-10-02 | Acs Dobfar S.P.A. | Process for producing nanoparticles of paclitaxel and albumin |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9221867B2 (en) | 2003-01-06 | 2015-12-29 | Angiochem Inc. | Method for transporting a compound across the blood-brain barrier |
US8969310B2 (en) | 2005-07-15 | 2015-03-03 | Angiochem Inc. | Potentiation of anticancer agents |
US9713646B2 (en) | 2005-07-15 | 2017-07-25 | Angiochem Inc. | Potentiation of anticancer agents |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
JP2015157825A (ja) * | 2008-04-18 | 2015-09-03 | アンジオケム,インコーポレーテッド | パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法 |
JP2011516587A (ja) * | 2008-04-18 | 2011-05-26 | アンジオケム,インコーポレーテッド | パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法 |
US8710013B2 (en) | 2008-04-18 | 2014-04-29 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
AU2009238187B2 (en) * | 2008-04-18 | 2014-03-06 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
US8828925B2 (en) | 2008-10-15 | 2014-09-09 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
US9173891B2 (en) | 2009-04-20 | 2015-11-03 | Angiochem, Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
US9161988B2 (en) | 2009-07-02 | 2015-10-20 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
US20130131174A1 (en) * | 2010-07-05 | 2013-05-23 | Eriochem | Injectable pharmaceutical formulation of melphalan |
US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
Also Published As
Publication number | Publication date |
---|---|
WO2007082978B1 (es) | 2007-09-07 |
EP1982699A1 (en) | 2008-10-22 |
EP1994925A1 (en) | 2008-11-26 |
AR054215A1 (es) | 2007-06-13 |
GT200800145A (es) | 2009-07-21 |
MX2008009358A (es) | 2008-09-10 |
NZ569968A (en) | 2011-07-29 |
EP1994925A4 (en) | 2013-01-23 |
RU2008133761A (ru) | 2010-02-27 |
US20090215882A1 (en) | 2009-08-27 |
MX2008009357A (es) | 2008-09-10 |
RU2429837C2 (ru) | 2011-09-27 |
ZA200805704B (en) | 2009-11-25 |
PE20071243A1 (es) | 2008-02-03 |
AU2007206876A1 (en) | 2007-07-26 |
PE20070945A1 (es) | 2007-10-07 |
ZA200805989B (en) | 2009-05-27 |
JP2009523771A (ja) | 2009-06-25 |
UY30099A1 (es) | 2008-09-02 |
CA2638034A1 (en) | 2007-07-26 |
NZ569783A (en) | 2011-04-29 |
US20090215883A1 (en) | 2009-08-27 |
BRPI0706931A2 (pt) | 2011-04-19 |
CA2637893A1 (en) | 2007-07-26 |
AU2007206877A1 (en) | 2007-07-26 |
BRPI0706932A2 (pt) | 2011-04-19 |
UY30100A1 (es) | 2008-09-02 |
WO2007082978A1 (es) | 2007-07-26 |
JP2009523770A (ja) | 2009-06-25 |
GT200800146A (es) | 2008-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007082979A1 (es) | Una composición sólida de taxano liofilizada, un procedimiento para preparar dicha composición sólida, una formulación farmacéutica y un conjunto (kit) de dicha formulación | |
US20220168285A1 (en) | Pharmaceutical compositions | |
ES2938586T3 (es) | Liberación de fármacos biodegradables para composiciones hidrófobas | |
ES2663324T3 (es) | Composiciones que comprenden docetaxel con estabilidad incrementada | |
JP5587198B2 (ja) | タキサン誘導体を含有する、安定性が改良された凍結乾燥医薬組成物、及びその製法 | |
ES2145115T4 (es) | Composiciones inyectables a base de derivados de taxanos. | |
Zhang et al. | Design of controlled release PLGA microspheres for hydrophobic fenretinide | |
US9801818B2 (en) | Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug | |
ES2854751T3 (es) | Un procedimiento para producir nanopartículas híbridas amorfas estables que comprende al menos un inhibidor de la proteína cinasa y al menos un componente polimérico estabilizante y formador de matriz | |
US20100255104A1 (en) | Pharmaceutical formulation of taxane | |
PT2197492E (pt) | Novas composições à base de taxóides | |
ES2358493B1 (es) | Nanopartículas pegiladas que comprenden una molécula biológicamente activa y sus aplicaciones. | |
EP3452031A1 (en) | Precision controlled load and release particles for post-operative pain | |
RU2370261C2 (ru) | Стабильная эмульсия для парентерального введения плохо растворимых в воде соединений, обладающих противоопухолевой активностью, и способ ее получения | |
WO2012029076A2 (en) | Stable pharmaceutical composition | |
ES2623758T3 (es) | Composición farmacéutica en la que se mejora la solubilidad de un derivado tricíclico parcialmente soluble | |
PL201335B1 (pl) | Liofilizowana kompozycja oraz zastosowanie liofilizowanej kompozycji | |
WO2011101865A2 (en) | Stable pharmaceutical compositions of clopidogrel for parenteral delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008550786 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/009357 Country of ref document: MX Ref document number: 2638034 Country of ref document: CA Ref document number: 2007206877 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569968 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1649/MUMNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007712570 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007206877 Country of ref document: AU Date of ref document: 20070119 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2007206877 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08085940 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2008-010221 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12161609 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0706932 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080718 |